Pemetrexed

Drug Profile

Pemetrexed

Alternative Names: Alimta; LY-231514; LY-231514 disodium; MTA; Multi-targeted antifolate; Pemetrexed disodium

Latest Information Update: 10 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Developer Eli Lilly; University of California, Davis; Virginia Commonwealth University
  • Class Antineoplastics; Benzamides; Glutamates; Hypoxanthines; Small molecules
  • Mechanism of Action Antimetabolites; Tetrahydrofolate dehydrogenase inhibitors; Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mesothelioma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Mesothelioma; Non-small cell lung cancer
  • Phase II Breast cancer
  • Phase I/II Solid tumours
  • No development reported Head and neck cancer; Non-Hodgkin's lymphoma; Osteosarcoma; Ovarian cancer; Renal cell carcinoma
  • Discontinued Small cell lung cancer

Most Recent Events

  • 05 Oct 2017 Patent Trial and Appeal Board of the USPTO ruled in the favor of Eli Lilly for patentability of the vitamin regimen for pemetrexed in USA
  • 07 Aug 2017 Eli Lilly completes a phase II trial for Non-small-cell-lung-cancer (Combination therapy, First-line therapy, Late-stage disease) in Germany (EudraCT2011-001963-37)(NCT01742767)
  • 13 Jun 2017 Roche plans a phase II/III trial for Non-small cell lung cancer(Monotherapy, Combination therapy, Inoperable/unresectable, Metastatic disease, Late-stage disease) in USA, Australia, Belgium, Brazil, Canada, France, Hong Kong, Italy, South Korea, Mexico, Poland, Spain and Thailand (NCT03178552)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top